Join Growin Stock Community!

Cardinal health inc(CAH.US AI Earnings Summary)

US StockHealthcare
No presentation for CAH

CAH AI Earnings Summary (In-Depth)

Last updated: 2026-11-05 (US time)

2027 Q1 (Fiscal Year)

Core Highlights

  • Stock Price Reaction: Cardinal Health beat expectations and raised its full-year earnings outlook; results were released before the U.S. market open on 11/5, and the stock closed at $267.82 that day (the first trading day after earnings), up 2.25% from the 11/4 close of $261.93.
  • Market Expectations: Non-GAAP diluted earnings per share (EPS) for the quarter was $3.26, which was approximately 10.9% higher than the market expectations of $2.94. The significant earnings beat was primarily driven by strong profits in the Pharmaceutical and Specialty Solutions segment and sustained robust product demand.
  • Performance vs. Previous Guidance: This quarter's Non-GAAP diluted EPS of $3.26 was 10.9% above the market expectations of $2.94; the full-year FY2027 Non-GAAP EPS guidance provided last quarter was $12.40–$12.60 (this is full-year guidance, not quarterly, and is not suitable for direct comparison with single-quarter actuals); Global Medical Products and Distribution (GMPD) segment profit was approximately $33M, against a full-year guidance range of $200M–$220M (full-year guidance, not single-quarter; management expects the low end); Adjusted Free Cash Flow was $1.583B against a full-year guidance of $3.5B–$4.0B (full-year guidance, not single-quarter).
  • In One Sentence: Cardinal Health reached a milestone with quarterly operating profit exceeding $1B and significantly raised its full-year EPS forecast due to strong growth in its Pharmaceutical and Specialty businesses, and the stock closed up 2.25% on 11/5, the first trading day after earnings.

Quarterly Highlights

Non-GAAP EPS significantly exceeded market expectations, leading to an upward revision of full-year guidance.

  1. Non-GAAP EPS beat market expectations by approximately 10.9%: Non-GAAP diluted EPS for the quarter reached $3.26, up 28% year-over-year, exceeding the $2.94 TradingView pre-earnings market expectation. CFO Aaron Alt noted that gross profit growth of 12% significantly outpaced the 9% growth in SG&A expenses, driving Non-GAAP operating income up 17% year-over-year to $1.001B, crossing the $1B milestone for the first time in a single quarter.

  2. Strong Pharmaceutical and Specialty Solutions segment profit drives full-year revision: The segment's profit reached $783M this quarter, up 17% year-over-year, with margins improving from 1.13% in the prior year to 1.25%. Management attributed this strong performance to healthy contributions from branded, generic, and specialty businesses, as well as continued sourcing value from the Red Oak Sourcing partnership, leading to an increase in full-year segment profit growth guidance from 8%–11% to 10%–12%.

  3. Specialty business grew 17%–19% year-over-year, exceeding double-digit expectations: During the Q&A, it was noted that specialty business growth reached approximately 17%–19%, higher than the original double-digit expectations, driven primarily by key areas in Urology and Oncology. GLP-1 medications continued to grow, contributing approximately 500 basis points to Pharmaceutical segment revenue growth, though offset by a 400 basis point revenue headwind from Inflation Reduction Act (IRA) drug pricing adjustments.

  4. CVS Health contract renewed through 2032, securing the revenue base: CEO Jason Hollar announced the completion of a contract renewal with its largest customer, CVS Health, extending the term to June 2032. The partnership is expected to continue following the planned CVS spin-off in 2028. In the past 12 months, CAH has renewed contracts representing nearly two-thirds of enterprise revenue, mostly under long-term agreements, providing a stable foundation for future investment.

  5. "Other" segment profit growth more than double revenue growth, full-year guidance raised again: The "Other" business segment, which includes at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics, saw revenue grow 7% to $1.764B, while profit grew 16% to $193M. Profit margins increased from 10.12% to 10.94% year-over-year. Consequently, the full-year segment profit growth guidance was raised from 15%–18% to 17%–20%.

  6. Strive Medical integration complete, expanding the Urology ecosystem: CEO Jason Hollar stated that the Strive Medical acquisition is complete, with all employees and volumes successfully transitioned to the national network, strengthening the home urological supplies distribution platform. This creates synergy with the Solaris acquisition and Specialty Networks' urology data services, providing CAH with full coverage in Urology from drug distribution to Management Services Organizations (MSO) and home care.

  7. Quarterly Adjusted Free Cash Flow reached $1.583B, maintaining capital allocation flexibility: Adjusted Free Cash Flow for the quarter increased 23% year-over-year (from $1.285B to $1.583B), with a quarter-end cash balance of $5.3B. During the period, a $500M accelerated share repurchase program was completed, and approximately $125M in dividends were paid, returning a total of $625M to shareholders while maintaining leverage near the midpoint of the target range.

  8. Global Medical Products and Distribution (GMPD) profit better than internal expectations: GMPD profit reached $33M this quarter. Although down from $46M in the same period last year, CFO Aaron Alt explicitly stated it was "above expectations." Cardinal Health brand product growth in the U.S. was in the low-to-mid single digits (1%–5%), and the deployment of autonomous robots (over 100 Locus robots across 12 distribution centers) continued to drive efficiency gains.

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer